Boston Scientific Corp. (NYSE:BSX) was founded in 1979. With a market cap over $110 billion, it is one of the largest publicly traded medical device companies in the world. The stock has significantly outperformed its competitors and the overall market over the past year. There Are Better Options Than Boston Scientific BSX Data by GuruFocus Segment breakdown Warning! GuruFocus has detected 5 Warning Sign with BSX. Boston Scientific operates in two segments: Cardiovascular and Medsurg. Cardiovascular accounts for over 60% of the revenue and includes devices and treatments related to monitoring, diagnosing and treating issues related to the heart. Medsurg accounts for the remaining 40% of revenue and includes devices and treatments related to digestion, urology and neurological disorders. Quarterly revenue is up for both segments, though the growth rate in the Cardiovascular segment is outpacing Medsurg. There Are Better Options Than Boston Scientific This is a great thing for Boston Scientific investors since the largest segment has the highest growth. But how will it fare going forward? The cardiovascular market is only expected to grow about 6% moving forward, significantly less than Boston Scientific's overall recent growth. There Are Better Options Than Boston Scientific If the company wants to maintain its elevated growth rate, it needs to be from taking share away from competitors. Fortunately, it is a smaller fish in a very large pond. Boston Scientific is big enough to be noticed, but has plenty of room to grow and steal some share from larger competitors. Earnings and guidance have been fantastic Boston Scientific turned it up a notch starting in March 2023 with earnings per share growing around 20% per year for each quarter. There Are Better Options Than Boston Scientific Further, earnings per share figures have been consistently beating Wall Street analyst expectations for these quarters by about 8% on average. Company guidance has also been improving. When Boston Scientific reported 2023 annual figures in January, it forecasted sales to grow around 9% and earnings to be near $2.25 per share for fiscal year 2024. Just three months later, the company increased its expected sales growth to 12% and earnings to nearly $2.31 when it released first-quarter 2024 results. This updated guidance would yield 13% growth in 2024 earnings per share compared to 2023. Wall Street analysts are optimistic for the future. The average price target is over $80, which is about 8% higher than current price levels. Valuation ratios are screaming overvalued Unfortunately, the valuation ratios for Boston Scientific are raising many red flags. Speaking of red, here is the GF Value Rank section: There Are Better Options Than Boston Scientific Let's discuss a few of these ratios in more detail. First, the current price-earnings ratio, which is in the mid-60s, is high and above historical values. The price-earnings without nonrecurring items ratio is a lot lower in the mid-30s. Earnings per share without NRI is the company's EPS after removing non-recurring items and is a better measure of a company's true EPS. For Boston Scientific, the non-recurring items are primarily amortization expenses, acquisition and divestment charges and restructuring expenses. Amortization expense is largely related to intangible assets. It is recurring, but not really considered operating, so it is removed from EPS without NRI. Last year, the price-earnings ratio without NRI was near 27, so current values are about 25% higher. Boston Scientific's ratio is also worse than its peers. Comparably, the multiple is higher than almost 70% of other medical device companies and 25% higher than the industry median. There Are Better Options Than Boston Scientific The PEG ratio is even worse. The major drawback to the price-earnings ratio is that it does not account for growth. This is where the PEG ratio can be more helpful because it divides the ratio by the expected long-term growth rate. For Boston Scientific, the PEG ratio is just below 5, which is really bad. Companies with PEG ratios above 2 are considered overvalued and Boston Scientific is more than double that. Comparison to its peers does not help. Boston Scientific's PEG ratio is higher than 80% of its competitors and more than double the industry median of 1.97. There Are Better Options Than Boston Scientific The GF Value for Boston Scientific is around $56, which is a lot lower than the current price and is thus designated as significantly overvalued. There Are Better Options Than Boston Scientific There are better options in medical devices The growth for Boston Scientific is definitely there, especially in the cardiovascular segment. However, I think the stock price has increased too much, especially relative to the competition, to make the stock a good investment. Here is Boston Scientific's PEG ratio relative to some of its competitors: There Are Better Options Than Boston Scientific Boston Scientific's PEG ratio is the highest in this comparison with a figure just below 5. Stryker Corp. (NYSE:SYK) is the only competitor with a similar PEG ratio near 4.50. Every other company is significantly lower with values near 2. The GF Score for Boston Scientific looks high at 84 with a growth score of 9, but has a value score of only 3. There Are Better Options Than Boston Scientific Other companies in the medical services industry have much better GF Scores. Stryker, which we just mentioned, has a higher GF score of 93. Abbott Laboratories (NYSE:ABT), a $200 billion market cap company in the medical devices industry, has a great score of 95. If you want to go smaller, Edwards Lifesciences Corp. (NYSE:EW) has a score of 98. There Are Better Options Than Boston Scientific Overall, Boston Scientific is not a terrible investment. Management appears to have turned the company around in the last year, and the stock performance reflects that. However, I think the share price ran up too high in the past year and the stock is overvalued. For investors interested in Boston Scientific, there are better opportunities elsewhere, especially within the medical device industry. If you already own some shares, I would significantly cut back your position (at least 50%) and move those gains somewhere else. This article first appeared on GuruFocus.
There Are Better Options Than Boston Scientific
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...